APREA THERAPEUTICS INC (APRE) Stock Price, Quote, News and Overview
NASDAQ:APRE - Nasdaq - US03836J2015 - Common Stock - Currency: USD
APRE Quote, Performance and Key Statistics
NASDAQ:APRE (5/2/2025, 8:00:01 PM)
1.8499
+0.04 (+2.2%)
The current stock price of APRE is 1.8499 USD. In the past month the price increased by 2.77%. In the past year, price decreased by -65.42%.
APRE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About APRE
Company Profile
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2019-10-03. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. The company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. The company also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
Company Info
APREA THERAPEUTICS INC
3805 Old Easton Road
Doylestown PENNSYLVANIA 02116 US
CEO: Christian S. Schade
Employees: 8
Phone: 12159484119
APREA THERAPEUTICS INC / APRE FAQ
What is the stock price of APREA THERAPEUTICS INC today?
The current stock price of APRE is 1.8499 USD. The price increased by 2.2% in the last trading session.
What is the ticker symbol for APREA THERAPEUTICS INC stock?
The exchange symbol of APREA THERAPEUTICS INC is APRE and it is listed on the Nasdaq exchange.
On which exchange is APRE stock listed?
APRE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for APREA THERAPEUTICS INC stock?
9 analysts have analysed APRE and the average price target is 10.71 USD. This implies a price increase of 478.95% is expected in the next year compared to the current price of 1.8499. Check the APREA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is APREA THERAPEUTICS INC worth?
APREA THERAPEUTICS INC (APRE) has a market capitalization of 10.23M USD. This makes APRE a Nano Cap stock.
How many employees does APREA THERAPEUTICS INC have?
APREA THERAPEUTICS INC (APRE) currently has 8 employees.
What are the support and resistance levels for APREA THERAPEUTICS INC (APRE) stock?
APREA THERAPEUTICS INC (APRE) has a resistance level at 3.07. Check the full technical report for a detailed analysis of APRE support and resistance levels.
Is APREA THERAPEUTICS INC (APRE) expected to grow?
The Revenue of APREA THERAPEUTICS INC (APRE) is expected to decline by -32.8% in the next year. Check the estimates tab for more information on the APRE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy APREA THERAPEUTICS INC (APRE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of APRE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of APRE, evaluating the profitability, health, valuation and growth aspects
- APREA THERAPEUTICS INC (APRE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- APREA THERAPEUTICS INC (APRE) Sales and EPS estimates to see what analysts future expectations are.
- APREA THERAPEUTICS INC (APRE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- APREA THERAPEUTICS INC (APRE) Insider and Institutional Ownership to learn about the owners and their transactions.
- APREA THERAPEUTICS INC (APRE) Stock Chart to make your own analysis
- APREA THERAPEUTICS INC (APRE) Latest news and press-releases to stay up to date.
Does APREA THERAPEUTICS INC (APRE) stock pay dividends?
APRE does not pay a dividend.
When does APREA THERAPEUTICS INC (APRE) report earnings?
APREA THERAPEUTICS INC (APRE) will report earnings on 2025-05-12, before the market open.
What is the Price/Earnings (PE) ratio of APREA THERAPEUTICS INC (APRE)?
APREA THERAPEUTICS INC (APRE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.38).
What is the Short Interest ratio of APREA THERAPEUTICS INC (APRE) stock?
The outstanding short interest for APREA THERAPEUTICS INC (APRE) is 1.36% of its float. Check the ownership tab for more information on the APRE short interest.
APRE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to APRE. When comparing the yearly performance of all stocks, APRE is a bad performer in the overall market: 96.2% of all stocks are doing better.
APRE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APRE. While APRE seems to be doing ok healthwise, there are quite some concerns on its profitability.
APRE Financial Highlights
Over the last trailing twelve months APRE reported a non-GAAP Earnings per Share(EPS) of -2.38. The EPS increased by 40.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.04% | ||
| ROE | -62.85% | ||
| Debt/Equity | 0 |
APRE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to APRE. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 36.19% and a revenue growth -32.8% for APRE